Expression of membrane glycoproteins and surface-bound rat IgG on platelets from antibody-treated mice*
| Injected antibody . | Anti-rat IgG FITC . | Anti-GPIIbIIIa FITC . | Anti-GPIbα FITC . | Anti-GPV FITC . | Anti-CD9 FITC . |
|---|---|---|---|---|---|
| PBS | 14.8 ± 2.0 | 313.8 ± 6.0 | 284.2 ± 9.6 | 167.7 ± 6.0 | 536.5 ± 9.9 |
| JON1 | 41.2 ± 3.5 | 27.7 ± 3.5 | 275.2 ± 8.5 | 152.2 ± 3.5 | 276.8 ± 8.7 |
| JON2 | 52.7 ± 4.6 | 31.2 ± 3.4 | 292.0 ± 16.2 | 161.5 ± 5.6 | 283.3 ± 8.6 |
| JON3 | 34.2 ± 4.4 | 34.2 ± 3.5 | 290.8 ± 9.2 | 163.0 ± 5.8 | 314.8 ± 10.2 |
| p0p3 | 72.2 ± 4.8 | 337.3 ± 9.7 | 81.7 ± 9.2 | 147.0 ± 6.3 | 606.2 ± 12.3 |
| p0p4 | 59.7 ± 5.7 | 337.0 ± 4.1 | 76.7 ± 3.6 | 141.3 ± 4.8 | 603.2 ± 7.0 |
| p0p5 | 99.7 ± 5.5 | 332.3 ± 4.5 | 72.3 ± 4.1 | 135.0 ± 5.5 | 602.8 ± 5.0 |
| EDL1 | 325.2 ± 5.3 | 282.8 ± 4.3 | 260.7 ± 5.2 | 158.0 ± 3.8 | 526.2 ± 4.3 |
| EDL2 | 294.0 ± 4.1 | 287.3 ± 3.9 | 287.7 ± 6.1 | 157.7 ± 5.4 | 551.3 ± 4.5 |
| EDL3 | 278.7 ± 5.7 | 303.3 ± 4.5 | 284.3 ± 3.7 | 158.8 ± 3.7 | 531.5 ± 3.8 |
| p0p1 | 407.8 ± 5.7 | 316.0 ± 5.3 | 273.0 ± 3.6 | 147.3 ± 3.1 | 534.3 ± 7.9 |
| p0p2 | 389.0 ± 4.4 | 305.5 ± 4.6 | 292.2 ± 4.3 | 157.7 ± 6.2 | 541.0 ± 3.7 |
| p0p6 | 421.8 ± 3.6 | 322.5 ± 4.2 | 284.5 ± 6.3 | 143.8 ± 4.0 | 531.2 ± 4.6 |
| DOM1 | 190.3 ± 3.6 | 308.3 ± 5.9 | 276.3 ± 4.9 | 145.7 ± 5.2 | 533.8 ± 6.8 |
| DOM2 | 214.3 ± 6.5 | 318.7 ± 4.8 | 277.0 ± 4.8 | ND | 520.2 ± 4.8 |
| DOM3 | 186.8 ± 5.3 | 322.5 ± 6.0 | 264.7 ± 7.0 | 138.5 ± 6.4 | 536.2 ± 6.3 |
| KIR1 | 43.5 ± 3.1 | 304.3 ± 7.3 | 296.2 ± 6.7 | 150.5 ± 3.8 | 534.3 ± 5.2 |
| KIR2 | 37.5 ± 3.8 | 324.2 ± 4.2 | 281.5 ± 6.5 | 146.7 ± 6.3 | 535.8 ± 6.3 |
| KIR3 | 37.8 ± 3.8 | 313.3 ± 7.2 | 288.8 ± 5.4 | 142.2 ± 6.9 | 542.0 ± 7.3 |
| Injected antibody . | Anti-rat IgG FITC . | Anti-GPIIbIIIa FITC . | Anti-GPIbα FITC . | Anti-GPV FITC . | Anti-CD9 FITC . |
|---|---|---|---|---|---|
| PBS | 14.8 ± 2.0 | 313.8 ± 6.0 | 284.2 ± 9.6 | 167.7 ± 6.0 | 536.5 ± 9.9 |
| JON1 | 41.2 ± 3.5 | 27.7 ± 3.5 | 275.2 ± 8.5 | 152.2 ± 3.5 | 276.8 ± 8.7 |
| JON2 | 52.7 ± 4.6 | 31.2 ± 3.4 | 292.0 ± 16.2 | 161.5 ± 5.6 | 283.3 ± 8.6 |
| JON3 | 34.2 ± 4.4 | 34.2 ± 3.5 | 290.8 ± 9.2 | 163.0 ± 5.8 | 314.8 ± 10.2 |
| p0p3 | 72.2 ± 4.8 | 337.3 ± 9.7 | 81.7 ± 9.2 | 147.0 ± 6.3 | 606.2 ± 12.3 |
| p0p4 | 59.7 ± 5.7 | 337.0 ± 4.1 | 76.7 ± 3.6 | 141.3 ± 4.8 | 603.2 ± 7.0 |
| p0p5 | 99.7 ± 5.5 | 332.3 ± 4.5 | 72.3 ± 4.1 | 135.0 ± 5.5 | 602.8 ± 5.0 |
| EDL1 | 325.2 ± 5.3 | 282.8 ± 4.3 | 260.7 ± 5.2 | 158.0 ± 3.8 | 526.2 ± 4.3 |
| EDL2 | 294.0 ± 4.1 | 287.3 ± 3.9 | 287.7 ± 6.1 | 157.7 ± 5.4 | 551.3 ± 4.5 |
| EDL3 | 278.7 ± 5.7 | 303.3 ± 4.5 | 284.3 ± 3.7 | 158.8 ± 3.7 | 531.5 ± 3.8 |
| p0p1 | 407.8 ± 5.7 | 316.0 ± 5.3 | 273.0 ± 3.6 | 147.3 ± 3.1 | 534.3 ± 7.9 |
| p0p2 | 389.0 ± 4.4 | 305.5 ± 4.6 | 292.2 ± 4.3 | 157.7 ± 6.2 | 541.0 ± 3.7 |
| p0p6 | 421.8 ± 3.6 | 322.5 ± 4.2 | 284.5 ± 6.3 | 143.8 ± 4.0 | 531.2 ± 4.6 |
| DOM1 | 190.3 ± 3.6 | 308.3 ± 5.9 | 276.3 ± 4.9 | 145.7 ± 5.2 | 533.8 ± 6.8 |
| DOM2 | 214.3 ± 6.5 | 318.7 ± 4.8 | 277.0 ± 4.8 | ND | 520.2 ± 4.8 |
| DOM3 | 186.8 ± 5.3 | 322.5 ± 6.0 | 264.7 ± 7.0 | 138.5 ± 6.4 | 536.2 ± 6.3 |
| KIR1 | 43.5 ± 3.1 | 304.3 ± 7.3 | 296.2 ± 6.7 | 150.5 ± 3.8 | 534.3 ± 5.2 |
| KIR2 | 37.5 ± 3.8 | 324.2 ± 4.2 | 281.5 ± 6.5 | 146.7 ± 6.3 | 535.8 ± 6.3 |
| KIR3 | 37.8 ± 3.8 | 313.3 ± 7.2 | 288.8 ± 5.4 | 142.2 ± 6.9 | 542.0 ± 7.3 |
Mice were bled 6 hours after injection of 100 μg of the indicated antibodies and platelets were stained for rat immunoglobulin G (IgG), GPIIbIIIa, GPIbα, GPV, and CD9 with fluorescein isothiocyanate (FITC)-labeled antibodies. Results are expressed as mean log fluorescence ± SD for 6 mice per group. ND = not determined.